Results 41 to 50 of about 12,783,707 (261)

The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer [PDF]

, 2010
<b>Background & aims:</b> The involvement of a systemic inflammatory response, as evidenced by the Glasgow Prognostic Score (GPS), is associated with weight loss and poor outcome in patients with non-small cell lung cancer.
Meek, C.L., Wallace, A.M., McMillan, D.C., Forrest, L.M.   +3 more
core   +1 more source

Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

Chinese Journal of Lung Cancer
For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients.
Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology
doaj   +1 more source

Increased HAGLR expression promotes non–small cell lung cancer proliferation and invasion via enhanced de novo lipogenesis

Tumor Biology, 2017
Lung cancers are broadly classified into small cell lung cancer and non–small cell lung cancer, with non–small cell lung cancer one of the leading causes of cancer-associated deaths worldwide.
Chunwei Lu, Jun Ma, Dingfang Cai
doaj   +1 more source

Recent progress in targeted therapy for non-small cell lung cancer

Frontiers in Pharmacology, 2023
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people’s health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the ...
Yanxia Xiao, Pu Liu, Jie Wei, Xin Zhang, Jun Guo, Yajun Lin, Yajun Lin   +6 more
doaj   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

Non-small-cell lung cancer: how to manage RET-positive disease

Drugs in Context, 2022
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti   +6 more
doaj   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G., Johnson, P.W.M., Harper, P. G., Qian, W., Rudd, R. M., Spiro, S.G., Gregory, W. M., Hatton, M., Eisen, T. G., James, L.E., Rankin, E. M., Johnson, P. W. M., Rankin, E.M., Spiro, S. G., Rudd, R.M., Lee, S. M., Littler, J. A. H., Lee, S.M., Littler, J.A.H., Eisen, T.G., Martin, W.M.C., Gregory, W.M., James, L. E., Gower, N. H., Martin, W. M. C., Gower, N.H.   +25 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer

BMC Cancer
Objectives The 9th edition of the lung cancer tumor-node-metastasis (TNM) staging system downgrades certain non-small cell lung cancer (NSCLC) patients from stage IIIA (T1N2) to IIB(T1N2a).
Tong Wu, Jingsheng Cai, Yun Li, Rongjing Xie, Kezhong Chen   +4 more
doaj   +1 more source